Sign In
Buy MDT
$85.39
-0.320 (-0.373%)
At Close: Jul 31, 2026
Stock Market Sell-Off: How I'm Continuing to Make Passive Income
09:02am, Sunday, 14'th Aug 2022 The Motley Fool
I love my dividend stocks, and since I'm still not retired, market downturns let me buy more of what I own as I reinvest my dividends.
Stock Market Sell-Off: How I'm Continuing to Make Passive Income
05:02am, Sunday, 14'th Aug 2022
I love my dividend stocks, and since I'm still not retired, market downturns let me buy more of what I own as I reinvest my dividends.
Undervalued Medtronic Sports Solid Dividend Growth Prospects
04:54pm, Friday, 12'th Aug 2022
Medtronic is a global leader in medical technology. The company functions in four operating segments: Cardiac & Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. It is a ste
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Lags Revenue Estimates
12:25pm, Friday, 12'th Aug 2022 Zacks Investment Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 11.43% and 24.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the s
Zevia (ZVIA) Reports Q2 Loss, Tops Revenue Estimates
12:25pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Zevia (ZVIA) delivered earnings and revenue surprises of -55.56% and 7.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bill George Talks About What Makes a Good CEO
11:10am, Thursday, 11'th Aug 2022 The Motley Fool
It starts with finding "true north."
Medtronic to announce financial results for its first quarter of fiscal year 2023
11:00am, Wednesday, 10'th Aug 2022
DUBLIN , Aug. 10, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of fiscal year 20
PetIQ (PETQ) Q2 Earnings Top Estimates
10:45pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
PetIQ (PETQ) delivered earnings and revenue surprises of 50% and 2.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Medtronic And Intuitive Surgical Poised For Big Growth?
10:28am, Tuesday, 09'th Aug 2022
Health care is one of the better-performing sectors in 2022, with medical gear makers Medtronic and Intuitive Surgical outpacing the broader industry recently.
Buy 4 S&P 500 August Dog Days Dividend Aristocrats
10:15pm, Monday, 08'th Aug 2022
"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. 65 Aristocrats screened as of August 4, 2022 repre
Medtronic (MDT) Gains As Market Dips: What You Should Know
09:50pm, Monday, 08'th Aug 2022 Zacks Investment Research
Medtronic (MDT) closed at $93.58 in the latest trading session, marking a +0.32% move from the prior day.
3 Stocks That Could Help You Retire a Millionaire
01:05pm, Sunday, 07'th Aug 2022 The Motley Fool
Million-dollar investing isn't all that complicated. It just requires finding names you can confidently sit on for years on end (as you should).
Q2 Earnings Scorecard and Analyst Reports for Visa, Comcast & Medtronic
05:06pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Today's Research Daily features updated earnings scorecard and fresh analyst reports on Visa (V), Comcast (CMCSA), Medtronic (MDT) & others.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
12:45pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.62% and 64.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance
05:58pm, Tuesday, 02'nd Aug 2022 Benzinga
Axonics Inc (NASDAQ: AXNX) reported a 50% Y/Y increase in Q2 sales to $69 million, beating the consensus of $59 million.
Sacral neuromodulation (SNM) revenue was $55.8 million, and Bulkamid revenue
